Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report)’s share price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.03 and traded as high as $0.03. Mateon Therapeutics shares last traded at $0.03, with a volume of 212,756 shares traded.
Mateon Therapeutics Stock Performance
The firm has a 50 day simple moving average of $0.03 and a 200-day simple moving average of $0.03.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Featured Stories
- Five stocks we like better than Mateon Therapeutics
- Upcoming IPO Stock Lockup Period, Explained
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- How to Use Stock Screeners to Find Stocks
- Oilfield Leader SLB: An AI Name You Need to Know
- 3 Stocks to Consider Buying in October
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
